Colistimethate Sodium - Sino Biopharmaceutical/Chia Tai Tianqing Pharmaceutical Group
Alternative Names: TQD-3524Latest Information Update: 19 Sep 2026
At a glance
- Originator Sino Biopharmaceutical
- Developer Chia Tai Tianqing Pharmaceutical Group; Sino Biopharmaceutical
- Class Antibacterials; Polymixins; Small molecules
- Mechanism of Action Cell membrane modulators
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Nosocomial pneumonia; Ventilator associated pneumonia
- Phase I Gram-negative infections
Most Recent Events
- 21 Jul 2026 Phase-II clinical trials in Nosocomial pneumonia in China (IV) (NCT07512596)
- 21 Jul 2026 Phase-II clinical trials in Nosocomial pneumonia in China (SC) (NCT07512596)
- 21 Jul 2026 Phase-II clinical trials in Ventilator-associated-pneumonia in China (IV) (NCT07512596)